Genmab — Februar 2015
-
-
Genmab/Jyske: Solide data om meget syge patienter
08:59
Jyske Bank har en positiv vurdering af de data, Genmab sent tirsdag udsendte om midlet Daratumumab til behandling af kræft i plasmacellerne i blodet, dobbelt-refraktær myelomatose.- Det er solide resultater, siger analytiker Frank Hørning Andersen.
Han venter, at Genmab-aktien vil reagere positivt på nyheden, til trods for at selskabets amerikanske ADRer faldt 8 pct. i tirsdagens handel i USA.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind